Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.-Reference-Cited by-同舟云学术

Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:8026-8026
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Goldman Jonathan Wade¹,Gandhi Leena²,Patnaik Amita³,Rosen Lee S.¹,Hilton John Frederick²,Papadopoulos Kyriakos P.³,Tolaney Sara M.²,Beeram Muralidhar³,Rasco Drew Warren³,Myrand Scott P.⁴,Beckmann Richard P⁴,Kulanthaivel Palaniappan⁴,Frenzel Martin⁴,Cronier Damien⁴,Chan Edward M.⁴,Flaherty Keith⁵,Wen Patrick Y.⁶,Tolcher Anthony W.³,Shapiro Geoffrey²

Affiliation:

1. UCLA Santa Monica Hematology-Oncology, Santa Monica, CA

2. Dana-Farber Cancer Institute, Boston, MA

3. South Texas Accelerated Research Therapeutics (START) Center for Cancer Care, San Antonio, TX

4. Eli Lilly and Company, Indianapolis, IN

5. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

6. Dana-Farber Cancer Center Institute, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.8026

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report;International Journal of Molecular Sciences;2023-02-20

2. Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials;Clinical and Translational Oncology;2021-08-07

3. Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study;JCO Precision Oncology;2020-11

4. CDK4/6 inhibitors: a novel strategy for tumor radiosensitization;Journal of Experimental & Clinical Cancer Research;2020-09-15

5. A rapid and sensitive bioanalytical LC–MS/MS method for the quantitation of a novel CDK5 inhibitor 20–223 (CP668863) in plasma: Application to in vitro metabolism and plasma protein‐binding studies;Biomedical Chromatography;2020-05-18